Clinical trial
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With…
NCT00225290 · TTY Biopharm, Industry · Terminated
Key facts
| NCT number | NCT00225290 |
|---|---|
| Title | Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve |
| Official title | Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve |
| Lead sponsor | TTY Biopharm, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Thalidomide(Thado) |
| Enrollment | 230 |
| Start date | Feb 1, 2003 |
| First posted | Sep 23, 2005 |
| Last update posted | Oct 12, 2011 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: